Key metabolite biomarkers demonstrate robust diagnostic potential for BCD (IMAGE)

Eye Discovery

Key metabolite biomarkers demonstrate robust diagnostic potential for BCD

Caption

(a) Heatmap of the top 10 differentially expressed metabolites. The left sidebar shows pathway classifications, and the top sidebar indicates sample groups (orange = patients with BCD; blue = controls). Notable elevation of pentose phosphate pathway metabolites and depletion of branched-chain amino acids are observed in patients with BCD. (b) ROC curves showing diagnostic performance for AMP (AUC = 0.877, 95% CI: 0.806–0.948), TG (34:1) (AUC = 0.860, 95% CI: 0.784–0.936), sedoheptulose 7-phosphate (AUC = 0.860, 95% CI: 0.844–0.929), and their combination (AUC = 0.957, 95% CI: 0.922–0.993). The dashed diagonal line represents random classification. (c) Bootstrap validation of the combined biomarker panel across 2000 iterations, demonstrating robust performance (AUC = 0.92–0.99, CV = 1.86%)

Credit

Yingke Zhao

Usage Restrictions

Credit must be given to the creator. Only noncommercial uses of the work are permitted.

License

CC BY-NC

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.